Yann d’Hervé Assumes Leadership of Evonik’s Health Care Business Line
Effective July 1, Yann d’Hervé will assume the role of leading Evonik’s Health Care business line.
Yann d’Hervé, previously heading the Care Solutions business line within Evonik’s Nutrition & Care division, brings a wealth of experience to his new position. He holds an MSc in Chemistry and an MBA, having joined REXIM SAS (France) in 1996, which later became part of the Health Care business line. During his tenure, Yann d’Hervé held various roles, including Business Analyst and Global Business Director for Wax Modifiers in the Oil Additives business line based in the U.S. His career at Evonik also includes serving as Vice President for Sales & Services Americas and subsequently as Vice President for Global Sales & Services, before relocating to Germany in 2020 to lead the Care Solutions business line.
Yann d’Hervé’s leadership is characterized by extensive expertise across manufacturing, finance, marketing, application technology, sales, and general management. He has overseen international operations and established strategic partnerships critical to business growth, emphasizing customer satisfaction and collaborative value creation.
Evonik Health Care collaborates with global pharmaceutical, medical, and nutritional companies to deliver innovative solutions. Its portfolio includes high-quality ingredients, delivery systems, and contract services aimed at advancing health and well-being.
Company Overview:
Evonik is a global leader in specialty chemicals, operating in over 100 countries worldwide. In 2022, the company achieved sales of €18.5 billion and an adjusted EBITDA of €2.49 billion. Evonik focuses on creating innovative, sustainable solutions across diverse industries, employing approximately 34,000 individuals dedicated to improving quality of life today and in the future.
Nutrition & Care Division:
The Nutrition & Care division of Evonik concentrates on enhancing health and quality of life through differentiated solutions. It serves resilient markets including active pharmaceutical ingredients, medical devices, human and animal nutrition, personal care, cosmetics, and household cleaning, generating €4.24 billion in sales in 2022 with about 5,700 employees.
Disclaimer:
This press release may contain forecasts, expectations, or statements concerning the future that involve known or unknown risks and uncertainties. Actual results may vary depending on changes in the operating environment. Evonik Industries AG and its group companies do not assume any obligation to update the forecasts, expectations, or statements presented in this release.
